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Recent advances in upper gastrointestinal lymphomas: molecular updates and diagnostic
implications
Approximately one-third of extranodal non-Hodgkin
lymphomas involve the gastrointestinal (GI) tract,
with the vast majority being diagnosed in the stom-
ach, duodenum, or proximal small intestine. A few
entities, especially diffuse large B-cell lymphoma and
extranodal marginal zone lymphoma of mucosa-asso-
ciated lymphoid tissue, represent the majority of
cases. In addition, there are diseases specific to or
characteristic of the GI tract, and any type of sys-
temic lymphoma can present in or disseminate to
these organs. The recent advances in the genetic and
molecular characterisation of lymphoid neoplasms
have translated into notable changes in the classifica-
tion of primary GI T-cell neoplasms and the recom-
mended diagnostic approach to aggressive B-cell
tumours. In many instances, diagnoses rely on mor-
phology and immunophenotype, but there is an
increasing need to incorporate molecular genetic
markers. Moreover, it is also important to take into
consideration the endoscopic and clinical presenta-
tions. This review gives an update on the most recent
developments in the pathology and molecular pathol-
ogy of upper GI lymphoproliferative diseases.
Keywords: differential diagnosis, duodenum, enteropathy-associated T-cell lymphoma, fluorescent in situ
hybridization, gastrointestinal lymphomas, indolent lymphoproliferative disorders, MALT lymphoma, molecular
pathology, small intestine, stomach
Introduction
Lymphomas involving the gastrointestinal (GI) tract
account for approximately 30–40% of extranodal
lymphomas.1,2 The notion of primary GI lymphomas,
in principle, refers to tumours arising in the GI tract
with the bulk of the tumour localised to a specific GI
organ, with or without regional involvement. By
extension, the term also encompasses situations in
which the clinical presentation is related to
lymphoma involvement of a GI site, and staging
reveals disseminated disease. In addition, the GI
tract can be affected by contiguous involvement or
dissemination of a systemic disease. Primary oeso-
phageal lymphomas are extremely rare, accounting
for <1% of GI lymphomas,2–4 with most cases prob-
ably representing extension from posterior mediasti-
nal masses or gastric primaries. The stomach alone
accounts for the majority of GI lymphomas (60% of
the cases), ~30% arise in the duodenum or small
intestine and ileocaecal region, and ~10% affect the
colon.1–6
Most GI lymphoma cases correspond to entities that
are not specific to the GI tract, with specific tumour
entities primarily arising in the GI tract representing
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a smaller proportion, including duodenal-type follicu-
lar lymphoma (FL) and intestinal T-cell lymphomas.
The prevalence of the different lymphoma entities
varies according to the site of involvement, i.e. stom-
ach versus duodenum and small intestine versus
colon (Table 1).
In this article, we present an update on the patho-
logical and molecular features of the lymphoid neo-
plasms that most commonly involve the upper GI
tract, with an emphasis on the new guidelines
derived from the latest updates of the World Health
Organization (WHO) classification of tumours of
haematopoietic and lymphoid tissues7 and the diges-
tive system,8 and a focus on more recent develop-
ments.
Small B-cell lymphomas
Although essentially any small B-cell lymphoma may
infiltrate the upper GI tract, primary GI presentation
is dominated by extranodal marginal zone lymphoma
of mucosa-associated lymphoid tissue (MALT lym-
phoma) in the stomach and the small intestine in
general, and duodenal-type FL in that specific site. A
diagnostic approach to lympho(plasma)cytic infiltrates
in the upper GI mucosa is shown in Figure 1, and
Table 2 summarises the antibodies commonly used to
assist in the differential diagnosis in routine practice.
M A L T L Y M P H O M A
MALT lymphoma, an indolent B-cell lymphoma reca-
pitulating the morphology and architectural features
of mucosa-associated lymphoid tissue (MALT),
accounts for 40–50% of primary gastric lymphomas
and a much smaller proportion (5–15%) of lym-
phomas arising in the small intestine.1–3,9,10 Patients
are usually adults and present with non-specific
symptoms such as dyspepsia, nausea, epigastric pain,
or bleeding, or may be asymptomatic. Immunoprolif-
erative small intestinal disease (IPSID) is a rare vari-
ant of intestinal MALT lymphoma associated with the
secretion of defective a heavy chains, and is largely
restricted to the eastern Mediterranean area, the Mid-
dle and Far East, and Africa. This disease, which usu-
ally develops in the duodenum and jejunum, affects
young adults of lower socioeconomic status and liv-
ing in poor hygienic conditions, who present with
malabsorption, diarrhoea, abdominal pain, and
weight loss.11,12
Association with infectious agents
MALT lymphomas usually occur in tissues naturally
devoid of MALT, and develop in a context of chronic
inflammation induced by infections or autoimmune
disorders.13,14 Epidemiological, biological and thera-
peutic studies have shown a strong link between Heli-
cobacter pylori infection and gastric MALT
lymphoma.15,16 Following an initial study by Wother-
spoon et al., several groups have confirmed that erad-
ication of H. pylori following antibiotic therapy
induces regression of MALT lymphoma in ~75% of
early-stage tumours.17–20 In earlier reports, H. pylori
infection was demonstrated in >90% of cases.21–23
However, recent analyses have shown a significant
reduction in the prevalence of H. pylori infection in
gastric MALT lymphomas in Europe as compared
with the early 1990s.24 In a retrospective study of
>400 cases diagnosed in France between 2002 and
2010, only 57% of the cases were associated with H.
pylori.25 Another point is that the density and
detectability of H. pylori have been reported to
decrease in association with lymphoma progres-
sion.26,27 In intestinal MALT lymphomas, an associa-
tion with Campylobacter jejuni infection has been
reported, but evidence for a causal link is lacking.28
Pathological features
Endoscopically, MALT lymphoma may present as sub-
tle gastritis-like lesions, erosions, and ulcerations, or
as diffuse infiltrates and thickened folds, which may
form polypoid or exophytic mass lesions. Endoscopic
Table 1. Relative prevalence of lymphomas in different















MALT lymphoma 40–50 5–15 25
Follicular lymphoma Rare 1–10 Rare
Mantle cell lymphoma <5 <5 25







ID, Immunodeficiency; MALT, Mucosa-associated lymphoid tissue.
© 2020 John Wiley & Sons Ltd, Histopathology, 78, 187–214.
188 P G Foukas et al.
ultrasonography is the most accurate staging method
for assessment of the depth of invasion and the status
of regional lymph nodes.29,30 The Lugano and Paris
staging systems are most commonly used, with the
second describing more accurately the depth of gas-
tric wall invasion, a parameter that may predict the
response to anti-H. pylori treatment.30
Histologically, the cardinal features of MALT lym-
phoma are: (i) a diffuse and/or nodular infiltrate of
neoplastic lymphoid B cells cytologically resembling
marginal zone B cells; (ii) lymphoepithelial lesions;
and (iii) reactive lymphoid follicles with germinal cen-
tres.31,32 The neoplastic population comprises small
to medium-sized lymphoid cells, with a centrocyte-like
or monocytoid appearance, which infiltrate diffusely
into the mucosa and frequently colonise reactive ger-
minal centres (Figure 2). There can be cytological
variation: some tumours contain a relatively monoto-
nous population, whereas others feature a mixture of
cell types. The neoplastic infiltrate also usually con-
tains scattered, large, transformed blastic cells resem-
bling centroblasts or immunoblasts. Plasma cell
differentiation is seen in ~30% of cases (Figure 3).
The neoplastic plasma cells may appear as normal
mature plasma cells, have crystalline inclusions in
the cytoplasm, or possess nuclei with Dutcher bodies.
Lymphoepithelial lesions, defined as the invasion of
individual gastric pits and/or glands by aggregates
(three or more) of neoplastic cells, often resulting in
oxyphilic changes in the epithelium, constitute a
characteristic feature of gastric MALT lymphoma, but
are found infrequently in MALT lymphomas of the
small intestine. The destruction and disintegration of
the epithelial structures induce degenerative epithelial
changes manifested by eosinophilic or oncocytic
metaplasia. Notably, although lymphoepithelial
lesions in the stomach are highly suggestive of MALT
lymphoma, occasional lymphoepithelial lesions may
be seen in florid gastritis, so they are not specific for
a diagnosis of malignancy. Moreover, other lym-
phomas may show epitheliotropism and produce
alterations resembling lymphoepithelial lesions. In
particular, epitheliotropism is a defining property of
monomorphic epitheliotropic intestinal T-cell lym-
phoma, which, by morphology alone, may mimic
MALT lymphoma in the stomach. Epitheliotropism is
commonly seen in extranodal natural killer (NK)/T-
cell lymphoma, which rarely involves the stomach,
and is occasionally encountered in other B-cell lym-
phoma types such as diffuse large B-cell lymphoma
(DLBCL) or, less commonly, mantle cell lymphoma
(MCL).
The lymphoma cells are positive for pan-B-cell anti-
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Figure 1. Diagnostic approach to lympho(plasma)cytic infiltrates in the gastrointestinal mucosa. CK, cytokeratin.
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negative for CD5, with aberrant coexpression of
CD43 in approximately one-third of the cases.33 The
rare cases of CD5+ MALT lymphoma must be
distinguished from small lymphocytic lymphoma
(SLL) and MCL. MALT lymphoma cells are negative
for the germinal centre markers CD10 and B-cell
Table 2. Antibodies used in the (differential) diagnosis of gastrointestinal B-cell lympho(plasma)cytic infiltrates




B-cell lineage antigens Usually strong and diffuse expression in B-cell lymphomas. Weak
CD20 staining in CLL/SLL. Reduced or absent CD20 expression in
patients with previous immunochemotherapy comprising anti-CD20




Weakly expressed in mantle cells of follicles
CD5 expression in CLL/SLL and MCL, rarely in MALT lymphoma, and
in a subset of DLBCLs NOS
CD10 Germinal centre B cells CD10 expression in FL, BL, and a subset of DLBCLs NOS (germinal
centre-B-cell like). Rarely positive in blastoid MCL. Positive in
reactive follicles in MALT lymphoma
CD21 Mature B cells and FDCs Helpful to identify reactive or neoplastic follicular structures in MALT
lymphoma and FL
CD23 Activated B cells, mantle B cells of follicles, FDCs CD23 expression CLL/SLL, and a subset of FLs and DLBCLs. Lack of
CD23 expression in MCL. Helpful to identify reactive or neoplastic
follicular structures in MALT lymphoma and FL
CD43 Pan-T-cell antigen, monocytes, activated B cells CD43 expression in MCL and CLL/SLL (most cases, but sometimes
not detectable on routine sections), positive in a subset of MALT
lymphomas
bcl-2 Antiapoptotic molecule down-regulated in germinal
centre B cells
bcl-2+ neoplastic follicles in FL
bcl-2-reactive follicles in MALT lymphomas
Lack of bcl-2 expression typical of BL
Expression in >50% of neoplastic cells defines bcl-2+ (bcl-2+) DLBCL;
usually very strong and diffuse positivity in BCL2-rearranged
lymphomas
bcl-6 Transcription factor of germinal centre B cells and
follicular helper T cells
bcl-6 expression in FL, BL, a subset of DLBCLs NOS, and high-grade
B-cell lymphomas
Cyclin D1 No expression by normal B cells. Positive
endothelial cells and macrophages are internal
controls
Very sensitive and highly specific marker for MCL. Also expressed in
some DLBCLs and in proliferation centres of CLL/SLL
LEF1 Activated T cells Expressed in CLL/SLL cells
SOX11 No known expression in normal lymphoid tissues Expressed in a subset of MCLs, useful to identify the rare cyclin D1-
negative MCL
Ki67 Nuclei of cycling cells Ki67 proliferative index reflective of high-grade and low-grade
entities. Usually low in small B-cell lymphomas, with residual Ki67-
high germinal centres in MALT lymphomas; prognostic factor in





B cells (membrane Ig expression) and plasma cells
(cytoplasmic Ig expression). Normal j to k ratio:
2:1
Restricted (monotypic) light chain expression in neoplastic cells versus
polytypic expression in reactive lymphoproliferations
Cytokeratins Surface epithelium, crypts and glands Demonstration of lymphoepithelial lesions
bcl-2, B-cell lymphoma 2; bcl-6, B-cell lymphoma 6; BL, Burkitt lymphoma; CLL, Chronic lymphoid leukaemia; DLBCL, Diffuse large B-cell
lymphoma; FDC, Follicular dendritic cell; FL, Follicular lymphoma; Ig, Immunoglobulin; LEF1, Lymphoid enhancer factor 1; MALT, Mucosa-
associated lymphoid tissue; MCL, Mantle cell lymphoma; NOS, Not otherwise specified; SLL, Small lymphocytic lymphoma; SOX11, SRY-
box transcription factor 11.
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lymphoma 6 (bcl-6), negative for the MCL markers
cyclin D1 and SRY-box transcription factor 11
(SOX11), and usually express B-cell lymphoma 2
(bcl-2). They are negative for IgD and express mono-
typic IgG, IgM or IgA with either kappa or lambda
light chain, a feature best demonstrated in cases with
plasmacytoid differentiation. Antibodies against ker-
atins highlight lymphoepithelial lesions, and follicular
dendritic cell markers, such as CD21, CD23, and
CD35, are useful for highlighting follicular structures
and identifying follicular colonisation. The Ki67 pro-
liferation index is low outside of residual germinal
centres. Immune receptor translocation-associated
protein 1 (IRTA1) was recently characterised as a
potentially useful biomarker with which to identify
MALT lymphomas and distinguish them from other
small B-cell lymphomas. IRTA1 belongs to a family of
immunoglobulin-like proteins that mediate B-cell
immune responses, and is normally expressed in
benign monocytoid B cells, some marginal zone cells,
and intraepithelial B cells.34 IRTA1 expression has
been reported in 40% to >90% of MALT lymphomas,
whereas other small B-cell lymphomas are, with few
exceptions, IRTA1-negative.35,36
Molecular genetics/pathogenesis
Adding to the growth signals provided by infiltrating
H. pylori-specific T cells,37,38 activation of the B-cell
receptor (BCR) and nuclear factor-jB (NF-jB) sig-
nalling pathways plays a major role in gastric MALT
lymphoma development. Sequence analysis of
immunoglobulin (IG) gene rearrangements shows evi-
dence of somatic hypermutations, with an active
ongoing somatic hypermutation machinery resulting
in intraclonal variation and a biased usage of certain
immunoglobulin heavy chain (IGH) genes, such as
IGHV3-7 and IGHV1-69, indicating a selective pres-
sure towards antigen-driven clonal expansion.39–43
Several recurrent chromosomal translocations are
associated with MALT lymphomas. They are mutu-
ally exclusive, and their relative frequencies vary with
the primary site of involvement. The most frequent in
the GI tract is the t(11;18)(q21;q21)/BIRC3–MALT1
translocation, found in approximately 25% of gastric
A B C
D E F
Figure 2. Gastric mucosa-associated lymphoid tissue lymphoma. A, Panoramic view showing a diffuse lymphoid infiltrate, disrupting the
glands and the muscularis mucosae [haematoxylin and eosin (H&E)]. B, A diffuse infiltrate of small centrocyte-like cells with moderate
amounts of clear cytoplasm, forming lymphoepithelial lesions (H&E). C, Cytokeratin immunostain highlighting the lymphoepithelial lesions.
D, Positivity for lambda light chains. E, Negativity for kappa light chains. F, Immune receptor translocation-associated protein 1 (IRTA 1)
positivity of lymphoma cells, especially pronounced among the subset of intraepithelial lymphocytes.
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and 10–50% of intestinal MALT lymphomas. Its
oncogenic activity is attributed to overexpression of
MALT1, which is an important mediator of activation
of the canonical and non-canonical NF-jB path-
ways.44–48 Other recurrent translocations, more com-
monly observed at extra-GI sites, have been reported
in <5% of GI MALT lymphomas in most published
series. They include the t(14;18)(q32;q21)/IGH–
MALT1, t(1;14)(p22;q32)/IGH–BCL10, and t(3;14)
(p14.1;q32)/IGH–FOXP1 translocations.49,50 In gas-
tric MALT lymphomas, the t(11;18)(q21;q21)
translocation is more prevalent in H. pylori-negative
cases, correlates with higher-stage disease, and is a
factor in the poor response to alkylating agents.51,52
Conversely, t(11;18)-positive MALT lymphomas are
less prone to transformation to DLBCL.53 When it is
present in H. pylori-positive cases, the t(11;18)(q21;
q21) translocation is predictive of non-response to or
relapse after antibiotic therapy.21,54 Therefore, fluo-
rescence in-situ hybridisation (FISH) testing for t
(11;18) is recommended at initial diagnosis or for the
cases that fail to respond to anti-H. pylori ther-
apy.30,55 The clinical significance of the infrequent
IGH–BCL10 rearrangement is not clear, although a
small study suggested that cases with t(1;14) or
strong nuclear expression of B-cell lymphoma 10
(bcl-10) most likely do not respond to H. pylori eradi-
cation.56
Other aberrations variably reported in gastric
MALT lymphoma are deletions of TNFAIP3/A20
(6q23), which encodes an inhibitor of NF-jB,
and trisomies/gains of chromosomes 3, 8, and
18.57–60
In recent years, a few studies have examined the
mutational landscape of MALT lymphomas by means
of whole exome sequencing or targeted next-genera-
tion sequencing (NGS) technologies.57,61–63 Distinct
genetic profiles were observed in MALT lymphomas
from different sites.63 Overall, only a small number of
gastric MALT lymphomas have been analysed, with
variations in the methodology in the different studies.
Recurrent mutations in genes involved in activation
of NF-jB signalling pathways, such as TRAF3 (33%)
and TNFAIP3 (25%), were identified, and in general
were mutually exclusive with the BIRC3–MALT1
translocation. Interestingly, MALT lymphoma essen-
tially lacks mutations in MYD88, CD79A, or







Figure 3. Gastric mucosa-associated lymphoid tissue lymphoma with marked plasmacytic differentiation. A, A panoramic view showing a
diffuse mucosal infiltrate with atrophy and rarefaction of the glands [haematoxylin and eosin (H&E)]. B, Lymphoepithelial lesions and a dif-
fuse plasmacytic infiltrate in the lamina propria (H&E). C, CD20 highlighting the aggregates of intraepithelial lymphocytes, and only a few
cells between the glands. D, Cytokeratin immunostain highlighting the lymphoepithelial lesions. E, Staining for lambda light chains of the
majority of plasma cells. F, A few were kappa chain-positive plasma cells.
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lymphomas characterised by constitutive NF-jB acti-
vation. Mutations are also found in genes related to
B-cell differentiation, notably NOTCH1 (11–25%), and
epigenetic modifications (CIITA, TBL1XR1, and TET2),
and in tumour suppressor genes.61 Mutations in
GPR34 and PIK3CD, which are frequently found in
MALT lymphomas of the salivary glands and thyroid,
have not been detected in gastric MALT lym-
phomas.63
Differential diagnosis
A common diagnostic challenge is differentiating gas-
tric MALT lymphoma from H. pylori-associated gastri-
tis. An expansile, destructive infiltrate, the cytological
characteristics of the infiltrating cells, Dutcher bodies,
infiltration of the muscularis mucosae and prominent
lymphoepithelial lesions favour lymphoma, but many
biopsies may lack some of these features. Monotypic
immunoglobulin expression and/or coexpression of
CD43 by the B cells establish malignancy. Morpho-
logical assessment with the Wotherspoon scoring sys-
tem helps in identifying the cases that may benefit
from clonality testing.19,64
Differentiating MALT lymphoma from other small
B-cell lymphomas, notably MCL, which shows trop-
ism for the GI mucosa, but also SLL/chronic lympho-
cytic leukaemia (CLL) and FL, can also be
challenging. Immunohistochemistry is key in estab-
lishing the correct diagnosis (see below). Because of
the morphological overlap between MCL and MALT
lymphoma, cyclin D1 immunohistochemistry should
be performed in all cases of GI small B-cell lym-
phoma.30 MALT lymphomas with extensive plasma-
cytic differentiation should be distinguished from
plasma cell neoplasia, either extramedullary plasma-
cytoma or dissemination of a multiple myeloma,
which occur rarely in the GI tract (Figure 4).65
Although large cells are typically present and
admixed with the small B cells in MALT lymphoma,
sometimes representing up to 20% of the total cells,
transformation to DLBCL should be considered when
sheets or confluent clusters of large, transformed cells
are found outside follicles. Clusters of at least 20 cells
or a proportion of >30% large cells are needed to
consider a diagnosis of large-cell transformation. Con-
versely, diffusely scattered large cells, representing 5–
10% or even up to 20% of the total population, are
not associated with a worse prognosis, as long as
they do not form clusters.66–68 If a component of
MALT lymphoma is noted in a gastric or intestinal
DLBCL, it should be mentioned in the report. Reactive
germinal centres in MALT lymphomas, which can be
identified by their germinal centre immunophenotype,
should not be mistaken as foci of large-cell transfor-
mation.
Follow-up biopsies in gastric MALT lymphomas
Irrespective of stage, H. pylori eradication is the initial
treatment of choice, and it is recommended that fol-
low-up biopsies are taken 2–3 months after treatment
and subsequently twice yearly for 2 years.30 The
evaluation of histological response is based on the
Groupe d’Etude des Lymphomes de l’Adulte (GELA)
scoring system.69,70 In this scheme, patients with
complete response or probable minimal residual disease,
in which small residual lymphoid aggregates are
recognised, should be managed with observation and
regular follow-up. Although molecular assays have
shown that such lymphoid aggregates may harbour
the same clonal IG gene rearrangements as the initial
lymphoma, molecular testing is not recommended, as
no firm correlation has been established between a
positive molecular test result and a higher risk of
relapse.71–73 Patients with responding residual disease
or no-change/stable disease can also be managed with
observation for several months, as long as they are
asymptomatic, because responses may occur as late
as >18 months after the completion of antibiotic ther-
apy.72,74 In patients not responsive to antibiotic ther-
apy or with progressive disease, there are several
therapeutic options, including radiation therapy,
chemotherapy, and/or immunotherapy.30
As higher rates of epithelial preneoplastic lesions
(intestinal metaplasia, atrophic gastritis, and dys-
plasia) and a six-fold increased risk for gastric adeno-
carcinoma have been reported in patients with
gastric MALT lymphoma,75–78 it is important, in fol-
low-up biopsies, not only to assess the lymphoid infil-
trates but also to screen the biopsies for
(pre)neoplastic epithelial lesions.
D U O D E N A L - T Y P E A N D P R I M A R Y I N T E S T I N A L F L
Primary intestinal FL accounts for 5–10% of primary
intestinal lymphomas overall, and affects middle-aged
to older adults. Approximately half of the cases occur
in the second portion of the duodenum,1,2,79,80 and
because these show distinct clinicopathological fea-
tures—duodenal presentation, low histological grade,
indolent behaviour, and excellent outcome—they are
now recognised as a distinct disease entity, namely
duodenal-type FL.7 FL cases developing elsewhere
along the GI tract, usually in the small intestine or
colon, are referred to as primary intestinal FL
(Table 3). Most duodenal-type FL cases are discovered
incidentally during upper GI endoscopy for
© 2020 John Wiley & Sons Ltd, Histopathology, 78, 187–214.
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surveillance of unrelated pathologies, such as gastri-
tis, gastro-oesophageal reflux disease, or other malig-
nancies, and only a minority of patients present with
mass effect symptoms such as obstructive jaun-
dice.79,81–83 Endoscopically, the lesions appear as one
or more nodules or small polyps in the second portion
of the duodenum, but multifocal involvement of more
distal regions of the intestine, mainly the jejunum, is
not uncommon.81,82 Duodenal-type FL is an indolent
disease for which a watchful waiting approach is gen-
erally recommended.82,84 Nodal involvement (stage
II) is a risk factor associated with progression.85 Only
a few case reports have documented transformation
to DLBCL.86–88 Non-duodenal-type FLs tend to pro-
duce larger symptomatic tumour masses that may be
obstructive or cause bleeding, and staging is essential
to differentiate primary intestinal disease from sec-
ondary GI involvement by a systemic (nodal) FL.
Pathological features
In duodenal-type FL (Figure 5A–D), the neoplastic
follicles expand the duodenal mucosa/submucosa
and show features of grade 1–2 FL, i.e. non-po-
larised neoplastic follicles composed primarily of
centrocytes with few centroblasts, and lacking a
starry-sky appearance, an attenuated mantle zone,
and infiltration of centrocytes in the lamina pro-
pria outside the follicles. The B cells are CD10+,
bcl-6+, and bcl-2+, with a low Ki67 proliferation
index. One characteristic feature of duodenal-type
FL is the frequent distribution of CD21+ CD23+
follicular dendritic cells at the periphery of the
neoplastic germinal centres, referred to as a ‘hol-
lowed-out’ appearance. Furthermore, duodenal-type
FL neoplastic cells preferentially express IgA over
IgM,89,90 and the mucosal homing receptors a4b7
integrin and CCR9 chemokine receptor, which
direct lymphocyte trafficking to the intestinal
mucosa.91,92
Non-duodenal-type FL (Figure 5E–G) tends to be
transmural, encompasses cases ranging from grade
1–2 to grade 3, and may be accompanied by sclero-
sis. It is histologically and phenotypically indistin-
guishable from systemic FL.
A B
C D E
Figure 4. Oesophageal involvement by multiple myeloma. A, A panoramic view showing a dense and diffuse mucosal infiltrate, and the
overlying normal epithelium [haematoxylin and eosin (H&E)]. B, The infiltrate consisted of sheets of plasma cells, ranging from mature to
atypical (H&E). C, Strong and diffuse CD138 positivity. D, Monotypic expression of kappa light chains. E, Absence of immunostaining for
lambda light chains.
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Molecular genetics
Both duodenal-type and other intestinal FLs harbour
the t(14;18)(q32;q21)/IGH–BCL2 translocation in the
majority of the cases. In duodenal-type FL, the active
somatic hypermutation machinery is related to the
expression of BTB and CNC homolog 2 (BACH2)
instead of activation-induced cytidine deaminase
(AID).83,93 In an effort to shed light on the molecular
differences between duodenal-type FL and nodal FL
and explain the indolent clinical behaviour of duode-
nal-type FL, recent studies analysed the genetic land-
scape of the neoplastic cells and the expression profile
of the immune microenvironment.94,95 Comparison of
the mutational landscapes of duodenal-type FL and
nodal FL showed no significant differences in the
mutation rates of the most recurrently altered genes,
including CREBBP, TNFRSF14/HVEM, and EZH2. In
contrast, duodenal-type FL showed fewer biallelic or
multiple mutations in the histone methyltransferase
KMT2D/MLL2 gene and a high frequency of muta-
tions in HVCN1 and EEF1A1, in 22% and 35% of
cases, respectively.94 Interestingly, HVCN1 mutations
were reported to correlate with longer progression-
free survival in patients with systemic FL.96
Conversely, factors related to the microenvironment
appear to play a significant role in duodenal-type FL
lymphomagenesis. Selective usage of the IGHV4 gene
segment in most cases indicates an antigen-driven
mechanism of lymphomagenesis.93,97 Furthermore,
gene expression analyses have shown a distinct
immune microenvironment profile in duodenal-type
FL, characterised by a chronic inflammation gene sig-
nature and overexpression of proinflammatory cytoki-
nes and chemokines such as CXCL6, TNFSF15,
CCL11, CXCL1, CCL21, and CCL20 with its ligand
CCR6, with consequent recruitment of Th17 and acti-
vated CD4+ T-helper cells into the lymphoma
microenvironment.94,95
M C L
MCL is an aggressive type of B-cell lymphoma,
accounting for approximately 3–5% of primary GI
lymphomas.2,98 MCL mainly affects elderly and pre-
dominantly male individuals. As a primary GI disease,
it may present as multiple mucosal polyps, so-called
multiple lymphomatous polyposis, more commonly in
the lower GI tract. 99,100 Gastric involvement mani-
fests as large cerebroid folds. Presenting symptoms
may include abdominal pain, weight loss, diarrhoea,
or bleeding. Staging frequently reveals widespread
extraintestinal disease (stage IV). Microscopic GI tract
involvement is also extremely frequent (84%) in
patients with systemic MCL.101,102
Pathological features
MCL is composed of a monotonous small to medium-
sized lymphoid cell population, with clefted nuclei,
indistinct nucleoli, and scant cytoplasm, that infil-
trates the mucosa and submucosa in a nodular or dif-
fuse fashion (Figure 6). Occasionally, infiltration of
epithelial structures is found, resembling lymphoep-
ithelial lesions.103 Two aggressive cytological variants
are recognised, namely blastoid and pleomorphic.
Immunophenotypically, the cells typically express
CD20, PAX5, CD5, CD43, IgD, bcl-2, and cyclin D1,
and are negative for CD23, CD10, and bcl-6. Rare
cases with aberrant phenotypes, namely CD5–,
CD10+, or bcl-6+, have been described. SOX11
expression is a useful diagnostic marker in the rare
cyclin D1– MCL cases.104 A Ki67 proliferation index
of >30% identifies patients with a poor prognosis, and
should be reported.7
Table 3. Key points in comparison between primary
intestinal and duodenal-type follicular lymphoma (FL)
Primary intestinal FL
<4% of primary GI
lymphomas
Duodenal-type FL
<4% of primary GI
lymphomas
Localisation Small and large
intestine






















Pathology Centrocytes and centroblasts
CD20+ CD10+ bcl-2+ bcl-6+
Most cases t(14;18)+ (IGH–BCL2)
Grade 1–2 > grade 3
bcl-6 and CD10 can be
down-regulated
All cases grade 1–2




bcl-2, B-cell lymphoma 2; bcl-6, B-cell lymphoma 6; FDC, Follicular
dendritic cell; GI, Gastrointestinal; LN, Lymph node.
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Molecular genetics
The characteristic genetic signature of MCL is the t
(11;14)(q13;q32) translocation resulting in IGH–
CCND1 fusion and cyclin D1 overexpression, whereas
cases that lack cyclin D1 expression often show alterna-
tive CCND2 or CCND3 rearrangements.105,106
Immunogenetic studies have shown a biased usage of
certain IGHV genes (IGHV3-21, IGHV4-34, IGHV1-8,
and IGHV3-23), suggesting antigen-driven selection,
whereas completely unmutated IGHV genes are
detected in ~30% of the cases, which have a worse
prognosis than cases with IGH somatic hypermuta-
tions.107,108 The genomic landscape of MCL is heteroge-
neous, and comprises mutations in genes involved in
DNA damage response (ATM and TP53) and Notch sig-
nalling (NOTCH1 and NOTCH2), and in genes affecting
RNA metabolism and splicing (EWSR1, DAZAP1, and
HNRNPH1). Mutations in TP53, SMARCA4, CELSR3,
CCND1 and KMT2D have been found to negatively
affect the response to venetoclax-based therapies.109–111
The median survival is 3–5 years, and the majority
of cases remain incurable, with multiple relapses.
Besides standard chemotherapy, treatment options
currently comprise many new drugs such as ibruti-
nib, lenalidomide, bortezomib, temsirolimus, and
venetoclax.112
S L L
Although rare cases of primary SLL of the GI tract
have been described,113 most of them represent sec-
ondary involvement in patients with known CLL. It
usually consists of a dense and diffuse infiltrate of
small round lymphocytes, which may constitute pro-
liferation centres. The lymphoma cells are CD20+
(often with heterogeneous or weak expression),
CD5+, CD23+, CD43+, cyclin D1, and lymphoid
enhancer binding factor 1 (LEF1)+.114,115 Secondary
lymphoid follicles or lymphoepithelial lesions typical







Figure 5. Intestinal follicular lymphoma. A–D, Duodenal-type follicular lymphoma. A, The lesion presented as a mucosal polyp with nodular
and partly diffuse involvement of the lamina propria [haematoxylin and eosin (H&E)]. B, Cytologically, most cells were small, resembling
centrocytes (H&E). C, Diffuse positivity for B-cell lymphoma 2 (bcl-2). D, CD21 immunostaining showing follicular dendritic-cell meshworks
pushed to the outer rim of the follicles. E–G, Primary follicular lymphoma of the small intestine. E, The lesion presented as a circumferential
and transmural infiltrate causing obstruction, and required surgical excision. F, A panoramic view of the intestinal wall involved by the lym-
phoma infiltrate (H&E). G, Neoplastic follicles associated with sclerosis, comprising in this case mostly centrocytes (H&E).
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Aggressive B-cell lymphomas
DLBCL, including the not otherwise specified (NOS)
type (DLBCL, NOS) and specific variants, is the most
common aggressive lymphoma of the upper GI
tract.2–6 Burkitt lymphoma (BL) and high-grade B-cell
lymphomas (HGBCLs) occur less frequently. Two
HGBCL entities were created in the revised WHO clas-
sification of lymphoid neoplasms, to classify a group
of aggressive B-cell lymphomas that are clinically and
biologically distinct from DLBCL, NOS and BL.
HGBCLs with MYC and BCL2 and/or BCL6 rear-
rangements [so-called double-hit (DH) or triple-hit
(TH) lymphomas; HGBCL-DH/TH] are defined by their
genetic features, irrespective of the morphology.
HGBCL, NOS encompasses cases previously termed
‘unclassifiable, with features intermediate between
DLBCL and BL’, or showing blastoid morphology, but
lacking DH/TH translocations.7,116
The current diagnostic approach to aggressive lym-
phomas of B-cell lineage according to the 2017 WHO
guidelines is summarised in Figure 7. The first level
of assessment remains cytomorphology, which
encompasses large cells (centroblastic, immunoblastic,
plasmablastic or anaplastic types), Burkitt-type mor-
phology (monomorphic medium-sized cells with baso-
philic cytoplasm, coarse chromatin and several
medium-sized nucleoli, densely packed and associated
with a starry-sky pattern), intermediate cases (com-
prising somewhat pleomorphic cells with features
intermediate between Burkitt cells and large cells,






Figure 6. Mantle cell lymphoma of the stomach. A, A panoramic view showing a dense basophilic lymphoid infiltrate [haematoxylin and
eosin (H&E)]. B, A monotonous infiltrate of small cells with irregular nuclei, adjacent to a residual gastric gland (H&E). C, CD20 positivity.
D, CD5 expression. E, Cyclin D1 nuclear positivity.
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pattern), and blastoid tumours (comprising medium-
sized cells with fine chromatin, indistinct nucleoli,
and scant cytoplasm). Cases with blastoid morphol-
ogy may represent blastoid MCL or lymphoblastic
neoplasms, which are best identified with an appro-
priate panel of immunostains. BL is a rather uniform
entity, and in cases with typical morphology the diag-
nosis is confirmed by the demonstration of the
expected immunophenotype (CD20+ CD10+ bcl-
2– bcl-6+ MYC+, and a Ki67 proliferation close to
100%), and association with Epstein–Barr virus (EBV)
infection in a subset of the cases. In cases with typi-
cal morphology and immunophenotype, confirmation
of a MYC rearrangement by the use of FISH is
optional; in cases showing deviations from the typical
features (mild cytological pleomorphism and bcl-2
expression), FISH studies are mandatory to assess the
MYC status and exclude a DH lymphoma (Figure 8).
The majority of lymphomas composed of large B cells
remain under the umbrella term of DLBCL, NOS.
However, specific entities that may occur as GI neo-
plasms, such as EBV+ entities (EBV+ DLBCL and
EBV+ mucocutaneous ulcer), plasmablastic lym-
phoma, and the solid form of primary effusion
lymphoma, have to be excluded, and FISH studies are
also mandatory to identify the small subset of large
B-cell lymphomas with MYC and BCL2 and/or BCL6
rearrangements, because these are classified as
HGBCL-DH/TH.7
D L B C L , N O S
DLBCL, NOS usually presents de novo, but some cases
represent transformation of a pre-existing systemic or
GI small B-cell lymphoma.5,6 In particular, transfor-
mation of systemic FL may occur in the small intes-
tine, whereas MALT lymphoma represents the most
common primary GI small B-cell lymphoma that
undergoes transformation to DLBCL. DLBCL usually
presents as symptomatic ulcerated tumour masses or
mucosal thickening. The majority of cases are loca-
lised (stage I or II) at diagnosis.117–119 The tumour is
composed of large or medium to large lymphoid cells,
with centroblastic and/or immunoblastic and, less
commonly, anaplastic morphology. The growth is dif-
fuse and obliterates the crypts or glands without the
formation of typical lymphoepithelial lesions. A small-









CD10+ BCL2- BCL6+ MYC+
Ki67 close to 100%, EBER+/–
MYC rearrangment*


























Figure 7. The diagnostic approach to high-grade B-cell lymphomas. ABC, activated B-cell-like; GCB, germinal centre B-cell-like; HGBCL-DH/
TH, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit/triple-hit). HGBCL, NOS, high-grade B-cell
lymphoma, not otherwise specified. *Demonstration of a MYC rearrangement may not be mandatory in cases with typical morphology and
immunophenotype.
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and the presence of residual follicular dendritic cell
meshworks may denote an underlying MALT lym-
phoma. The lymphoma cells express pan-B-cell anti-
gens (CD20, CD19, CD22, CD79a, and PAX5) and
monotypic surface and/or cytoplasmic immunoglobu-
lin, usually IgM, and rarely coexpress CD5.118 A sub-
set of gastric DLBCLs are associated with H. pylori
infection, and there have been sporadic case reports
and one prospective study suggesting that H. pylori
eradication might be an effective treatment for lim-
ited-stage de-novo H. pylori-positive gastric
DLBCLs.120–122 In a recent retrospective study from
China, it was found that a positive H. pylori status in
gastric DLBCL was associated with a higher propor-
tion of stage I–II disease and was a predictor of less
aggressive behaviour and better outcome.117 It is
mandatory, according to WHO recommendations,
that DLBCL, NOS be classified into ‘germinal centre
B-cell-like (GCB)’ and ‘non-GCB’ or ‘activated B-cell-
like (ABC)’ subtypes.7 In diagnostic practice, this is
usually achieved by means of immunohistochemical
algorithms designed as surrogates of mRNA-based
expression signatures. The Hans classifier, based on
the assessment of three markers (CD10, bcl-6, and
MUM1) is one of the most widely used.123 Other
alternatives incorporating other markers, such as
FOXP1 and/or GCET-1, have been proposed.124 Meth-
ods based on mRNA expression profiling that are
applicable to routinely processed samples are also
available, e.g. the Lymph2Cx assay or multiplex liga-
tion-dependent probe amplification (MLPA) assay, but
they are less widely used.125,126 In the stomach, the
non-GCB/activated cases outnumber tumours with a
GCB immunophenotype (58–70% versus 30–
42%)68,117,118,127,128; conversely, intestinal DLBCLs
are more often of the GCB type.129–131 Those trans-
formed from MALT lymphomas are more often
CD10– and bcl-2– than are de-novo DLBCLs, but usu-
ally express bcl-6.26,127,132 The diagnostic work-up of
DLBCL, NOS should also include the assessment of
bcl-2 and MYC expression, with positive cut-offs set
at 50% of cells with cytoplasmic bcl-2 expression and
40% with MYC+ nuclei. Many cases are immunohis-





Figure 8. High-grade B-cell lymphoma with concomitant rearrangement of MYC and BCL2 (double-hit lymphoma). A, A low-power view
showing a diffuse mucosal basophilic infiltrate [haematoxylin and eosin (H&E)]. B, Cytomorphology was intermediate between medium and
large cells, with a focal starry-sky pattern (H&E). C, Strong CD10 positivity. D, The Ki67 proliferation index was very high. E, Lack of B-cell
lymphoma 2 (bcl-2) expression as shown by use of the usual Dako antibody (clone 124). F, Conversely, the clone E17 bcl-2 antibody
demonstrated diffuse bcl-2 expression. This pattern was probably due to a BCL2 mutation interfering with immunoreactivity of the epitope
recognised by the Dako clone 124 antibody.
© 2020 John Wiley & Sons Ltd, Histopathology, 78, 187–214.
Upper gastrointestinal lymphomas 199
or MYC rearrangements. Importantly, the so-called
‘double-expressor’ bcl-2+/MYC+ status (Figure 9)
identifies a group of patients who have more aggres-
sive disease and poorer outcomes.133,134
Although a subset of primary gastric DLBCLs arise
by transformation of MALT lymphomas, specific
translocations associated with MALT lymphoma, such
as the t(11;18)/BIRC3–MALT1 translocation, are rare
in DLBCLs, supporting the view that these cases are
less prone to transform.135 Regarding the recurrent
translocations associated with DLBCL, BCL2 rear-
rangements are overall rarely found in primary GI
DLBCL, and ~10% carry MYC translocations, which
is similar to the rate in nodal cases.136–139 BCL6
rearrangements, which have been found in associa-
tion with transformation of MALT lymphoma, are
present in 48% of gastric DLBCLs and 30% of intesti-
nal DLBCLs.132,139 Some studies suggest that BCL6
rearrangements may be associated with a better prog-
nosis.127,140 Recently, two seminal studies using a
multiplatform genomic approach, consisting of gene
expression profiling, whole exome sequencing, struc-
tural variants, and DNA copy number analysis, led to
the identification of several genetic subgroups based
on enrichment of driver mutations and signalling
pathways.141,142 Interestingly, both studies identified
a genetic subgroup defined by the association of
structural alterations of BCL6 and NOTCH2 muta-
tions, encompassing both non-GCB and GCB gene
expression signatures, which may be related to mar-
ginal zone lymphomas.
E B V - A S S O C I A T E D D I S E A S E S
A variety of large B-cell lymphoma entities are char-
acterised by a more or less frequent association with
EBV infection (Table 4).7 Overall these entities are
rare, but may involve the GI tract. They have in com-
mon the tendency to occur in individuals with some
dysfunction of the systemic or local immune system.
Given the spectrum of EBV-associated entities, the rel-
evance of EBV testing for proper diagnosis, and the
clinical importance of recognising EBV-associated
entities, we advocate performing EBV testing by
means of in-situ hybridisation for EBV-encoded small







Figure 9. Gastric diffuse large B-cell lymphoma, not otherwise specified. A,B, Diffuse mucosal infiltrate comprising large lymphoid cells
[haematoxylin and eosin (H&E)]. C, Strong B-cell lymphoma 2 (bcl-2) expression. D, MUM1 positivity in the majority of nuclei (this case had
an overall activated B-cell-like immunophenotype). E, Nuclear positivity for MYC was present in the majority of nuclei. F, The Ki67 prolifera-
tion index was high.
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EBV+ DLBCL, NOS (Figure 10) and EBV+ mucocu-
taneous ulcer include a broad range of clinicopatho-
logical features, ranging from highly aggressive
diseases to self-limited localised conditions, with some
overlap between the two entities.143 The lesions con-
tain EBV+ CD20+ large cells, often including scattered
Reed–Sternberg-like cells, and a polymorphic inflam-
matory background. The immunophenotype is usu-
ally of the activated B-cell type, with frequent CD30
expression, but a subset of cases are CD10+.144 EBV+
DLBCL, NOS is generally reported in patients without
any known immune deficiency disorder (after exclu-
sion of ‘specific’ types of EBV+ DLBCL, such as plas-
mablastic lymphoma), and can occur at any age, but
usually in older adults. In a series from Asia, EBV+
DLBCLs represented approximately 7–10% of gastric
primaries, and the presence of EBV was negatively
correlated with outcome.119 EBV positivity was found
to correlate with higher expression of programmed
death-ligand 1 (PD-L1) in the tumour microenviron-
ment, a finding that might have therapeutic impact
in the immunotherapy era.118 EBV+ mucocutaneous
ulcer causes superficial ulcerative lesions in the skin
or mucosae in elderly individuals, in the setting of
iatrogenic immunosuppression (methotrexate, aza-
thioprine, cyclosporine, mycophenolate) for rheuma-
toid arthritis or inflammatory bowel disease, in
human immunodeficiency virus (HIV)-infected indi-
viduals, or post-transplantation.145–147 Whereas
EBV+ mucocutaneous ulcer has a predilection for the
lower GI tract, a recent study from Japan reported
that GI EBV+ DLBCLs occurring in non-immunosup-
pressed individuals have a predilection for the stom-
ach, which was the main localisation of disease for
low-stage lesions and was often involved in cases
with multifocal lesions.144
Plasmablastic lymphoma is composed of large cells,
ranging from immunoblasts to plasmablasts with or
without a component of mature plasma cells, and is
characterised by extinction of the B-cell transcription
programme and a plasma cell immunophenotype.148
Recent data provide evidence that the transcriptome of
plasmablastic lymphoma is more closely related to that
of multiple myeloma than to that of other B-cell malig-
nancies.149 The GI tract is the most common site of
presentation, after the oral cavity, and ~50% of pri-
mary GI plasmablastic lymphomas are diagnosed in
the stomach or proximal small intestine.150–153
Although plasmablastic lymphoma was initially
described in HIV+ individuals, the majority of cases
nowadays occur in HIV– patients with other causes of
immunosuppression or apparently immunocompe-
tent.151,154,155 Plasmablastic lymphoma is essentially
negative for CD45, CD20, and PAX5, negative or vari-
ably positive for CD79a, and positive for CD38, CD138,
and VS38c, with expression of the transcription factors
PRDM1/BLIMP-1, MUM1, and XBP1. Epithelial mem-
brane antigen (EMA) and CD30 are also commonly
expressed. Cytoplasmic immunoglobulin is detected in
50–70% of the cases, and CD56 is variably
expressed.150,151,153 Approximately half of the cases
are EBV+ (EBER+; Epstein–Barr nuclear antigen 1
(EBNA1)+).150,151,153 MYC rearrangements are found
in 50% of the cases, usually with an IG gene as the
translocation partner.151–153,156 Recent NGS-based
studies have reported recurrent mutations affecting the
JAK–STAT (STAT3, JAK1, SOCS1, JAK2, and PIM1),
RAS–mitogen-activated protein kinase (MAPK) (NRAS,
KRAS, BRAF, and MAP2K1) and Notch (NOTCH1,
SPEN, and NCOR2) signalling pathways, providing the
genetic basis for new therapeutic interventions.149,157
Table 4. Epstein–Barr virus (EBV)-associated B-cell lympho-
proliferations
Entities defined by EBV association
EBV+ diffuse large B-cell lymphoma
EBV+ mucocutaneous ulcer
DLBCL associated with chronic inflammation
Lymphomatoid granulomatosis
Primary effusion lymphoma (EBV+ and HHV-8+)




Lymphoproliferative disorders associated with primary immune
deficiencies
Indications for EBER testing
Elderly individuals
Large-cell proliferations presenting as ulcers
DLBCLs with a non-GC immunophenotype
CD30 expression, Reed–Sternberg-like cells
Plasmablastic lymphoma
Clinical context: HIV+, post-transplantation, immune
deficiencies, children
DLBCL, Diffuse large B-cell lymphoma; EBER, Epstein–Barr virus-
encoded small RNA; GC, Germinal centre; HHV-8, Human her-
pesvirus 8; HIV, Human immunodeficiency virus.
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T-cell neoplasms
GI T-cell neoplasms are overall markedly less frequent
than B-cell lymphomas, but they encompass several
distinct entities. Although the majority of the cases
develop in the intestine, a small proportion of the
cases may arise in or disseminate to the stomach,
duodenum or, uncommonly, oesophagus. The
recently revised WHO classification introduced signifi-
cant changes in the classification of intestinal T-cell
lymphomas. The two subtypes of enteropathy-associ-
ated T-cell lymphoma (EATL), types I and II, which
were previously considered to be variants of the same
disease, have been reclassified as two distinct diseases
[EATL, formerly type I EATL, and monomorphic
epitheliotropic intestinal T-cell lymphoma (MEITL),
formerly type II EATL], owing to differences in their
epidemiology and clinical features, morphology, phe-
notype, and genetic features, as highlighted in recent
studies.7,158,159 Intestinal T-cell lymphoma, NOS is a
novel category created to include the cases of primary
intestinal T-cell lymphoma not meeting the criteria
for either EATL or MEITL. In addition, indolent T-cell
lymphoproliferative disorder of the GI tract (ITLDP)
represents a newly recognised group of clonal
monomorphic proliferations of small T cells showing
a superficial/mucosal distribution along the GI tract,
and usually characterised by indolent behaviour and
a chronic relapsing course.160,161 NK-cell enteropathy
(NKCE) represents another rare indolent disorder
derived from NK cells. Other mature T/NK-cell lym-
phoma entities, such as extranodal NK/T-cell lym-
phoma, nasal type (ENKTCL), can also primarily or
secondarily involve the GI tract, and their diagnosis
may be challenging.
E A T L
EATL, the most common form of primary intestinal
T-cell lymphoma, is a neoplasm derived from intraep-
ithelial T cells, and occurs in individuals with coeliac
disease (CD) (gluten-sensitive enteropathy). The
prevalence is highest in Europe, and especially north-
ern Europe, whereas the disease is essentially non-ex-
istent in Asia.162–165 The median age at presentation
is >60 years. Patients typically have a history of CD
or refractory CD (RCD), but a substantial proportion
of the cases arise de novo, and these may be
A B
C D E F
Figure 10. Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma, not otherwise specified. A, Diffuse involvement of the gastric mucosa
by an ulcerated eosinophilic lymphoproliferation [haematoxylin and eosin (H&E)]. B, A high-power view showing medium-sized to large lymphoid
cells with fine chromatin, and nucleoli, associated with single-cell necrosis and apoptosis (H&E). C, EBV-encoded small RNA (EBR) in-situ hybridisa-
tion was positive in most cells. D, Strong positivity for CD20. E, Lack of CD10 expression. F, A Ki67 proliferation index of >90%.
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associated with a better outcome. Patients with EATL
present with GI symptoms that often culminate in
intestinal perforation and peritonitis, or obstruction.
B symptoms are common (30–40%). EATL most com-
monly affects the small bowel, and rarely the large
intestine or stomach (8% of the cases).163,164 Lesions
are frequently multifocal. The prognosis is poor, with
a median survival of 7 months.166
Pathological features
EATL (Figure 11) presents as ulcerative lesions or
tumour masses. Histologically, EATL is composed of
pleomorphic, medium-sized to large, occasionally
anaplastic, lymphoid cells with a high mitotic rate. A
mixed inflammatory infiltrate is typically present, usu-
ally rich in histiocytes and eosinophils, and may some-
times obscure the lymphoma cells.8 Angiocentricity and
angioinvasion can lead to extensive necrosis. Entero-
pathic features [villous atrophy, crypt hyperplasia, and
increased intraepithelial lymphocytosis (IEL)] may be
seen in the adjacent or distant mucosa. The neoplastic
cells are CD2+ CD3+ CD4 CD5 CD7+ CD8/+
CD56 with an activated cytotoxic phenotype and a
high Ki67 index. CD30 is usually expressed by a large
proportion of cells.167 The majority of the cases are neg-
ative for T-cell receptor (TCR) expression (‘TCR-silent’);
~25% are positive for TCRab, and TCRcd expression
has been described in a few cases. Expression of CD103
(human mucosal lymphocyte antigen 1, integrin aEb7),
which is found in normal intraepithelial lymphocytes, is
often at least partially preserved. Overexpression of p53
is seen in many cases.
Molecular and genetic features
Clonal T-cell receptor (TR) gene rearrangements are
detected in the majority of the cases.168–170 EATL
shows multiple chromosomal imbalances: 9q gains
and almost mutually exclusive losses at 16q12.1,
gains of chromosome 7, frequent gains of chromo-
somes 1q and 5q, and losses involving 8p22–23.2,
16q21.1, 11q14.1–q14.2, and 9p21.2–p21.3.158,171–
175 The mutational landscape of EATL is charac-
terised by recurrent activating mutations in genes of
the JAK–STAT pathway, most commonly JAK1 and
STAT3, and rarely JAK3, STAT5B, TYK2, and







Figure 11. An enteropathy-associated T-cell lymphoma presenting as a subcardial gastric ulcer. A, A macroscopic view of the gastrectomy
specimen showing a large, ulcerated subcardial lesion. B, The tumour consisted of a pleomorphic, predominantly large-cell, lymphoid infil-
trate, including cells with anaplastic-type morphology (haematoxylin and eosin). C, Strong CD7 expression. D, CD30 positivity was detected
in most cells. E, An activated cytotoxic phenotype highlighted by perforin expression. F, Lack of T-cell receptor (TCR)-bF1 expression in the
neoplastic cells (in contrast to the few reactive lymphocytes in the field) (TCRd was also negative in this case, which was overall TCR-silent).
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pathway (KRAS, NRAS, and BRAF) are present in
20% of the cases, and TP53 mutations have been
reported in 10–15% of the cases. Alterations in
SETD2 are less common than in MEITL.
Whole transcriptome sequencing showed differ-
ences in the gene expression profiles of EATL and
MEITL, further supporting their reclassification as dis-
tinct entities.158 Genes expressed at higher levels in
EATL include STAT3, STAT5A, IRF1/4, and TGM2,
which encodes transglutaminase 2, a known
autoantigen in CD, highlighting the association of
EATL with this disorder. Furthermore, EATL was also
characterised by overexpression of interferon-c sig-
nalling pathway genes, a pattern reported in
untreated CD patients.177
Differential diagnosis
The diagnosis of EATL in the upper GI tract may be
challenging, especially that of de-novo cases if entero-
pathic features are not identified. In those instances,
if the pathological findings are consistent, a diagno-
sis of EATL should be proposed, and tested with
serological investigations and human leukocyte anti-
gen genotyping. In cases with no evidence of CD, a
diagnosis of intestinal T-cell lymphoma, NOS is more
appropriate. Cases with an anaplastic large-cell mor-
phology and strong CD30 expression may histologi-
cally resemble anaplastic large-cell lymphoma
(ALCL), but primary intestinal ALCL is very rare,
and this diagnosis can be considered only after thor-
ough clinical investigation to exclude underlying
CD.
A clinical context of RCD may raise the differential
diagnosis between EATL and type II RCD. Type II
RCD features villous atrophy and intraepithelial
expansion of slightly atypical lymphocytes, which are
usually monoclonal and immunophenotypically
abnormal, similar to that found in EATL, including
loss of surface CD3 expression by flow cytometry, and
loss of CD4 and CD8 expression. However, type II
RCD is an ‘in-situ’ precursor to EATL, lacking the
inflammatory background, predominantly large-cell
morphology, infiltration with possible mass formation,
necrosis and angioinvasion seen in EATL. CD30
expression is rarely seen in type II RCD, and is con-
sidered to be a sign of progression to EATL.8,178
M E I T L
MEITL is a lymphoma derived from intraepithelial
lymphocytes. It is unrelated to CD, and is composed
of medium-sized cells with round nuclei and pale
cytoplasm, featuring epitheliotropism to the adjacent
mucosa and lacking the inflammation and necrosis
characteristic of EATL. MEITL occurs worldwide, but
is the main form of primary intestinal T-cell lym-
phoma in Asia.163,179,180 The disease occurs in older
adults, with a male predominance.
Patients may have non-specific symptomatology,
such as abdominal pain and diarrhoea, or present
with perforation, obstruction, abdominal masses,
bleeding, or ascites. MEITL usually involves the jeju-
num, and less commonly the ileum or duodenum,
sometimes with concurrent colonic lesion(s). Presen-
tation in the colon or stomach is rare. Dissemination
to regional lymph nodes and various distant organs
may occur. The bone marrow is rarely involved
(5%).180–183 The prognosis is universally poor, despite
aggressive treatment, and the median overall survival
is 7–14.8 months.179,180
Pathological features
MEITL (Figure 12) usually presents as an ulcerated,
sometimes bulky, mass. The tumour comprises mono-
tonous, small to medium-sized lymphoid cells with
pale cytoplasm, dispersed chromatin, and inconspicu-
ous nucleoli. Some cases show some pleomorphism
but, unlike in EATL, there is no prominent inflamma-
tory infiltrate, and necrosis is limited to the surface.
The peritumoral mucosa shows prominent epithe-
liotropism and lesser involvement of the submucosa
and muscularis propria. The distant mucosa may
contain patchy foci with increased IEL without villous
atrophy.179,181,183,184 Nevertheless, rare reports of
cases with concomitant CD challenge the sporadic
nature of the neoplasm.185
Immunohistochemically, the tumour cells are typi-
cally CD2+, CD3+, CD7+, CD4, and
CD5.163,176,179,181,183 Most cases are positive for
CD8, CD56, and TIA1. Granzyme B is detected in
two-thirds of the cases. Aberrant expression of CD20
or other B-cell antigens occurs in 20% of the cases,
and CD30 is mostly negative. Either TCRab or TCRcd
is usually expressed, whereas a small subset are TCR-
silent.179–181,186,187 MATK expression has been
reported as a characteristic marker in the majority of
the cases.179,188 A recent study identified spleen tyro-
sine kinase (SYK) as a distinctive marker for MEITL
(95% versus 0% in EATL), pointing to a role of
enhanced TCR signalling in MEITL.186 EBER expres-
sion may be seen in scattered B cells, but is consis-
tently absent in the neoplastic T cells.
Molecular and genetic features
The majority of cases show monoclonal rearrange-
ments of the TR genes.179,180,189 Genomic copy
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number alterations in common with EATL include
gains of chromosomes 9q, 1q, and 7q.158,172,184
Alterations of chromosome 8, i.e. loss or gain of 8q,
which includes MYC, are significantly more frequent
in MEITL than in EATL.172,179 A characteristic fea-
ture of MEITL consists of SETD2-disruptive mutations
or deletions, which are present in >90% of the
cases.159 SETD2 encodes a lysine methyltransferase
responsible for trimethylation of lysine 36 in histone
H3. Immunohistochemically, SETD2-mutated cases
have undetectable or reduced SETD2 expression, with
concomitant low expression of histone H3 trimethy-
lated on lysine 36.159 Mice with SETD2 loss showed
expansion of cd T cells, suggesting novel roles of the
gene in T-cell development and an early event in
lymphomagenesis.158 Inactivation of SETD2 has been
demonstrated in many different tumour types, and
seems to play a role in both disease initiation and dis-
ease progression.190 Other genes mutated in MEITLs
and related to epigenetics include the histone acetyl-
transferase gene CREBBP (26%) and EP300, EZH2,
and ARID1, which are frequently mutated in B-cell
lymphomas, whereas other genes that are frequently
mutated in peripheral T-cell lymphomas (PTCLs),
such as TET2, DNMT3A, and IDH1/2, are usually
wild-type in MEITLs.159
Mutations activating the JAK–STAT pathway (espe-
cially in STAT5B, JAK3, and SH2B3) are present in a
large proportion of the cases. Mutually exclusive
alterations affecting the MAPK pathway (BRAF,
KRAS, NRAS, and TP53) are observed more fre-
quently than in EATL, collectively in ~80% of the
cases.159,176 Mutations of GNAI2, which is a gene
encoding a subunit of guanine nucleotide-binding
protein, have been reported in 21% of MEITLs.191
Whole transcriptome sequencing analysis showed
that genes overexpressed in MEITL as compared with
EATL include FASLG, SYK, TGBR1, and NCAM1
(consistent with CD56 expression).158 Furthermore,
enrichment for an NK-like cytotoxic signature, a
known function of intraepithelial lymphocytes, was
detected in MEITL.192
Differential diagnosis
The features of MEITL are usually sufficiently distinc-
tive from those of EATL. Even if an increase in IEL
may be seen in the mucosa distant from MEITL, vil-





Figure 12. Monomorphic epitheliotropic intestinal T-cell lymphoma involving the duodenum. A, A dense lymphoma infiltrate obliterating
the mucosa and submucosa [haematoxylin and eosin (H&E)]. B, Medium-sized cells densely infiltrating the lamina propria and showing
epitheliotropism to Brunner’s glands (H&E). C, Strong TIA1 expression. D, Diffuse positivity for CD56. E, Heterogeneous CD8 expression.
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CD56 (and CD8) may suggest a diagnosis of ENKTCL
(Figure 13), but MEITL is EBV–. In some cases,
expression of B-cell markers may be confusing, and
lead to consideration of a B-cell lymphoma.
Indolent T/NK-cell entities
I N D O L E N T T - C E L L L Y M P H O P R O L I F E R A T I V E
D I S O R D E R ( I T L P D ) O F T H E G I T R A C T
ITLPD of the GI tract is a new provisional entity
defined as a clonal T-cell lymphoproliferation involving
the GI mucosa, usually following a chronic and indo-
lent course.7 ITLPD can occur at any age, but it usu-
ally occurs in middle-aged adults, with a slight male
predominance (1.5:1). Symptoms include diarrhoea,
vomiting, bloating, and abdominal pain. Some patients
have been misdiagnosed as having RCD, and others
have a history of inflammatory bowel disease, autoim-
munity, or infection.161,193,194 Mucosal involvement is
frequently multifocal, with a predilection for the small
bowel and colon rather than the stomach. Mesenteric
lymph nodes may be enlarged. Isolated cases of pro-
gression to other sites have been reported.161,193–197
Most patients are alive with persistent disease after sev-
eral years of follow-up. Complete remission has been
reported in two cases,161,198 and death from disease
progression has been reported at 10–27 years after
diagnosis in seven patients.194,196,199–201
Pathological features
Endoscopy may show nodules, mucosal polyps, fis-
sures, and erosions. Some cases have no mucosal
anomalies. Histologically, ITLPD features a non-de-
structive proliferation of small, monomorphic lympho-
cytes, which may infiltrate the muscularis mucosae
or submucosa, and is associated with crypt hyperpla-
sia. Mitoses and apoptoses are both inconspicuous;
vascular invasion and necrosis are absent. Villous
atrophy is infrequent, but IEL may be encountered.
Scattered granulomas, lymphoid follicles or admixed
eosinophils may be seen. Transformed cases comprise
atypical cells and resemble PTCL.
Immunohistochemically, ITLPD is positive for CD3,
CD2, and TCRbF1.161,194,201 Some cases show down-
regulation or loss of CD5 and/or CD7 expression.
Most reported cases are CD4+, and less frequently
CD8+, but double-negative (CD4 CD8) or double-
positive (CD4+ CD8+) immunophenotypes have been
described. They are negative for T follicular helper-
cell markers. A recent study investigating the cell of
origin found that the CD4+ and double-positive cases
A B
C D E
Figure 13. Extranodal natural killer/T-cell lymphoma, presenting in the stomach. A,B, Diffuse mucosal infiltrate comprising pleomorphic medium-
sized to large cells (haematoxylin and eosin); note some epitheliotropism (A) and focal necrosis (B). C, Diffuse CD3 expression. D, Positivity for T-
cell receptor-d. E, Positivity for Epstein–Barr virus by in-situ hybridisation.
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featured Th1 (T-bet+), Th2 (GATA3+) or hybrid Th1/
Th2 (T-bet+ GATA3+) profiles, whereas the majority
of CD8+ cases and the double-negative cases showed
a Th2-polarised (GATA3+) phenotype.194 CD8+ cases
express TIA1, but are negative for other cytotoxic
markers. CD103 may be expressed, CD56 is usually
negative, and there is no association with EBV. The
Ki67 proliferation index is typically very low (<5%).
In one case, aberrant expression of CD20 was
observed. Transformed cases may express MUM1/
IRF4, CD30, CD25, perforin, and granzyme B.
Molecular genetics
Genetic data on ITLPD are scarce, but indicate a
burden of genetic aberrations lower than that in
EATL/MEITL, and suggest a different pathogenesis
for CD4+ and CD8+ cases.161,194,201 A study focused
mostly on CD8+ ITLPD did not find phospho-STAT3
expression or STAT3 mutations.161 A STAT3–JAK2
fusion was reported in four of five cases of CD4+
ITLPD by Sharma et al.,201 but a lower prevalence
was found in subsequent studies, and the fusion has
not been identified in CD8+, CD4+ CD8+ or
CD4 CD8 cases.194 Cases harbouring the STAT3–
JAK2 fusion show phosphorylation of STAT5, and
might be sensitive to JAK inhibitors.201,202 STAT3
mutations and SOCS1 deletion are other recurrent
alterations found essentially in CD4+ cases.161,194
Other genetic aberrations include loss-of-function
mutations in epigenetic modifier genes (TET2,
DNMT3A, and KMT2D) and structural alterations of
IL2 in CD8+ cases.194
Differential diagnosis
ITLPD should be distinguished from inflammatory dis-
orders, and from primary intestinal lymphomas. This
distinction is particularly important, because the nat-
ural history is completely different, and ITLPDs do
not either require or respond to chemotherapy. Clues
to the correct diagnosis include the superficial nature
of the lesions; the absence of mass formation and/or
a destructive growth pattern; the bland cytology;
and, the low proliferation index.
N K - C E L L E N T E R O P A T H Y ( N K C E ) / L Y M P H O M A T O I D
G A S T R O P A T H Y
NKCE was introduced in 2011 to designate indolent
GI mucosal lymphoproliferations derived from NK






Figure 14. Natural killer-cell enteropathy involving the stomach (lymphomatoid gastropathy). A–D, Morphological features consisting of a
mucosal infiltrate between the glands or partially destructive (C,D), composed of medium-sized cells with clear cytoplasm (B,D) (haema-
toxylin and eosin). E, CD3 immunopositivity. F, Perforin expression. G, CD56 expression. H, The Ki67 proliferation index was high in this
case. Note that, on next-generation sequencing analysis, this case had a small in-frame hotspot deletion in JAK3.
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evidence to substantiate NK-cell lymphoma.203 The
disorder was first described in the stomach, and has
also been reported as ‘lymphomatoid gastropa-
thy’.204–206 NKCE is a rare disease, with <50 cases
documented so far (reviewed in Dargent et al.; see ref-
erences therein).178,203–209 Most cases occurred in
middle-aged to older individuals, who were either
asymptomatic or presented with mild and rather non-
specific GI symptoms. The majority of the cases
occurred in the stomach, duodenum, or several upper
GI sites, or involved both the upper and lower GI
mucosa. Several gastric cases had concomitant H.
pylori infection. The clinical course entails sponta-
neous resolution or persistence of the lesions for up
to several years in some patients, despite various
types of therapy. Unlike ITLPD of the GI tract, it has
not yet been shown to progress to a more aggressive
disease or cause nodal involvement.
At endoscopy, the altered mucosa often consists of
erythematous, flat or polypoid lesions, superficial ero-
sions, or ulcers. Histologically (Figure 14), NKCE fea-
tures an atypical diffuse lymphoid infiltrate composed
of medium-sized to large cells, with moderate clear or
slightly eosinophilic cytoplasm, fine nuclear chro-
matin, and inconspicuous nucleoli. The infiltrate
expands the lamina propria, with occasional epithe-
liotropism and glandular destruction, but lacks angio-
centricity and necrosis. The atypical cells feature a
CD2+/ CD3+ CD4 CD5 CD7+ CD8/+ CD56+ NK-
cell immunophenotype, with an activated cytotoxic
profile. The Ki67 proliferation index is variable, and
is sometimes elevated.203,205–208 The cells in NKCE
are EBV–, which is a major feature distinguishing it
from ENKTCL.
All cases lack clonal TR gene rearrangements, con-
sistent with an NK-lineage derivation. In a recent
study using a large haematology-oriented NGS panel,
a somatic JAK3 mutation consisting of a small in-
frame deletion in exon 12 was identified in three of 10
NKCE cases.207 Other non-recurrent mutations involv-
ing PTPRS, AURKB, AXL, ERBB4, IGF1R, PIK3CB,
CUL3, CHEK2, RUNX1T1, CIC, SMARCB1 and SETD5
were found in other cases.207 These findings support
the neoplastic nature of the disorder, and may suggest
potential therapeutic targets in some patients.207
Conclusion
A variety of lymphomas occur in the upper GI tract,
and they are primarily diagnosed on endoscopic biop-
sies, which pose specific challenges, owing to limited
sampling. The diagnosis of lymphoid infiltrates in
these tissues primarily relies on careful morphological
assessment complemented by immunophenotypic
studies. Clonality assays, FISH studies and additional
molecular genetic tests are complementary tools that
are becoming increasingly useful or even mandatory
to provide complete characterisation and accurate
categorisation of the tumours. Importantly, endo-
scopic and clinical features are essential for providing
a correct interpretation of the rare T-cell prolifera-
tions encountered in the stomach or small intestine.
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